ARWR Arrowhead Pharmaceuticals
$61.54 -1.30%
US Stock · Health Care
RSI (14) · 30 / 70 bands
MACD (12, 26, 9)
Solid = close · dashed = 50-day MA · bars = volume. Toggle Bollinger / RSI / MACD. Hover to inspect. EOD data.
1D
-1.30%
YTD
+68.40%
P/E
—
P/B
10.04
ROE
-60.5%
Div yield
—
Beta
1.57
Market cap
$9.1B
RSI (14)
27
Next earnings
Nov 23, 2026
Previous session
close of Oct 6, 2026 · EOD, no live order bookOpen
$62.86
Close
$61.54
VWAP (n/a)
—
Day high
$63.19
Day low
$60.56
Volume
1.7M
VWAP = daily turnover ÷ volume — the volume-weighted average, the closest EOD read on where trading actually clustered. A true order book is live-only and needs a broker feed. Turnover/VWAP available for MOEX listings.
Latest headlines
Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
Yahoo Finance · Sep 29
ARWR Stock: Goldman Sachs Resumes Coverage With $74 Target As Clinical Catalysts Near
Yahoo Finance · Sep 24
Arrowhead Pharmaceuticals (ARWR) On ARO DIMER PA Data And Whether Undervaluation Still Holds
Yahoo Finance · Sep 19
Arrowhead Pharmaceuticals Spotlights Dual-Target RNAi Data, Plozasiran Launch Progress
Yahoo Finance · Sep 19
Arrowhead Pharmaceuticals Eyes SHTG Filing as RNAi Pipeline Expands
Yahoo Finance · Sep 18
RNA Interference Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Silence Therapeutics
Yahoo Finance · Sep 18
Headlines via Yahoo Finance · links open the source · not an endorsement.
Recent SEC filings
8-K Aug 4, 2026 View → 10-Q Aug 4, 2026 View → 8-K Jun 16, 2026 View → 10-Q May 7, 2026 View → 8-K May 7, 2026 View →
Source: SEC EDGAR · opens the official filing.
Research & reports
External resources — availability and opinions are theirs, not ours.
This is reference data for your own analysis — not a recommendation to buy or sell ARWR. Try it in the Lab to size a position and see the risk.